Skip to main content
Melissa Johnson, MD, Oncology, Nashville, TN, TriStar Centennial Medical Center

MelissaLynneJohnsonMD

Oncology Nashville, TN

Thoracic Cancer

Director, Lung Cancer Research Associate Director, Drug Development Unit-Nashville Sarah Cannon Research Institute Tennessee Oncology, PLLC

Dr. Johnson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Johnson's full profile

Already have an account?

Summary

  • Dr. Melissa Johnson is the Director of the Lung Cancer Research Program at Sarah Cannon Research Institute and the Associate Director of the Drug Development Unit in Nashville. She is also a partner in Tennessee Oncology, PLLC. She is a medical oncologist affiliated with TriStar Centennial Medical Center. She received her medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 13 years. She specializes in thoracic oncology and clinical trial investigation.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2007
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2004

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2020 - Present
  • TN State Medical License
    TN State Medical License 2021 - 2025
  • TN State Medical License
    TN State Medical License 2014 - 2025
  • LA State Medical License
    LA State Medical License 2020 - 2022
  • AL State Medical License
    AL State Medical License 2020 - 2020
  • IL State Medical License
    IL State Medical License 2010 - 2017
  • NY State Medical License
    NY State Medical License 2006 - 2011
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors. 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
  • A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced sol... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cance... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
  • Join now to see all

Press Mentions

  • Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009
    Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009January 4th, 2023
  • Domvanalimab-Containing Regimens Show Activity in PD-L1-High NSCLC
    Domvanalimab-Containing Regimens Show Activity in PD-L1-High NSCLCDecember 28th, 2022
  • AstraZeneca’s Imfinzi with Imjudo Approved in the US for NSCLC
    AstraZeneca’s Imfinzi with Imjudo Approved in the US for NSCLCNovember 11th, 2022
  • Join now to see all

Professional Memberships

Hospital Affiliations